Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18984595 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2024 | July 2025 | Allow | 6 | 2 | 0 | No | No |
| 18906588 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18742215 | METHOD FOR MAKING PLURIPOTENT STEM CELLS | June 2024 | September 2024 | Allow | 3 | 0 | 0 | No | No |
| 18649790 | Adenoviral Vector Transduced Apheresis Product | April 2024 | January 2025 | Allow | 9 | 2 | 1 | Yes | No |
| 18358659 | GENETICALLY MODIFIED STEM CELLS | July 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18316198 | MODIFIED B CELLS AND METHODS OF USE THEREOF | May 2023 | March 2024 | Allow | 10 | 2 | 1 | No | No |
| 18315782 | USING REPROGRAMMED, PERSONALIZED CANCER STEM CELLS AS A TRIPLE-KILLER CANCER TREATMENT | May 2023 | February 2025 | Abandon | 21 | 2 | 1 | No | No |
| 18166700 | Activatable Cytokine Polypeptides and Methods of Use Thereof | February 2023 | April 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18087618 | SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT | December 2022 | October 2023 | Allow | 10 | 1 | 0 | No | No |
| 17934811 | ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF | September 2022 | April 2024 | Allow | 19 | 2 | 1 | No | No |
| 17948313 | ALLELE EDITING AND APPLICATIONS THEREOF | September 2022 | March 2025 | Allow | 30 | 1 | 0 | No | No |
| 17931576 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | September 2022 | April 2024 | Allow | 19 | 1 | 0 | No | No |
| 17823448 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | February 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 17823445 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | January 2024 | Allow | 17 | 2 | 0 | No | No |
| 17823419 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | July 2024 | Allow | 22 | 4 | 0 | No | No |
| 17823454 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | February 2024 | Allow | 17 | 3 | 0 | No | No |
| 17821703 | NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE | August 2022 | May 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17817751 | HUMAN MONOCLONAL ANTIBODIES TO FUCOSYL-GM1 AND METHODS FOR USING ANTI-FUCOSYL-GM1 ANTIBODIES | August 2022 | May 2025 | Allow | 33 | 1 | 1 | No | No |
| 17817885 | COMPOSITION FOR DETERMINATION OF CELL-MEDIATED IMMUNE RESPONSIVENESS | August 2022 | April 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17817281 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | October 2022 | Allow | 2 | 1 | 0 | No | No |
| 17817207 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | November 2022 | Allow | 4 | 3 | 0 | No | No |
| 17817232 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | February 2023 | Allow | 6 | 3 | 0 | Yes | No |
| 17817279 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | October 2022 | Allow | 2 | 1 | 0 | No | No |
| 17817239 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | May 2023 | Allow | 9 | 3 | 0 | No | No |
| 17817273 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | June 2024 | Allow | 22 | 3 | 0 | Yes | No |
| 17817226 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | November 2022 | Allow | 3 | 2 | 0 | No | No |
| 17817276 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | October 2022 | Allow | 2 | 6 | 0 | No | No |
| 17817217 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | May 2023 | Allow | 9 | 2 | 0 | No | No |
| 17817247 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | June 2023 | Allow | 10 | 2 | 0 | No | No |
| 17872741 | COMBINED ORGAN AND HEMATOPOIETIC CELLS FOR TRANSPLANTATION TOLERANCE OF GRAFTS | July 2022 | February 2025 | Allow | 30 | 1 | 0 | No | No |
| 17856997 | GENERATING CIK NKT CELLS FROM CORD BLOOD | July 2022 | October 2023 | Allow | 16 | 2 | 1 | Yes | No |
| 17810537 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | March 2023 | Allow | 8 | 2 | 0 | Yes | No |
| 17810542 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | June 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17810482 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | February 2023 | Allow | 8 | 2 | 0 | No | No |
| 17856800 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | August 2022 | Allow | 2 | 1 | 0 | No | No |
| 17856806 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | June 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17856793 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | April 2023 | Allow | 9 | 3 | 0 | No | No |
| 17810540 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | March 2023 | Allow | 8 | 4 | 0 | Yes | No |
| 17842212 | SYSTEMS AND METHODS FOR CELL CULTURING | June 2022 | January 2025 | Allow | 31 | 1 | 0 | No | No |
| 17827089 | PREPARATION OF A THERAPEUTIC COMPOSITION FOR TREATING AUTOIMMUNE DISEASES | May 2022 | March 2025 | Abandon | 33 | 7 | 1 | Yes | No |
| 17804239 | GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MULTIPLE TUMOR ANTIGENS OR MULTIPLE VIRUSES | May 2022 | June 2025 | Allow | 36 | 1 | 1 | No | No |
| 17734907 | Optimization of Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | May 2022 | March 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17698920 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17669891 | ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | February 2022 | May 2024 | Allow | 27 | 0 | 0 | No | No |
| 17578172 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | January 2022 | December 2024 | Allow | 34 | 1 | 0 | No | No |
| 17569943 | CULTURE CONTAINER, METHOD FOR CULTURING LYMPHOCYTES, CULTURE-CONTAINER PRODUCTION METHOD, AND SOLID-PHASING APPARATUS | January 2022 | December 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17567470 | BISPECIFIC ANTIBODIES FOR USE IN STEM CELL TRANSPLANTATION | January 2022 | December 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17544534 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | December 2021 | July 2022 | Allow | 7 | 1 | 0 | No | No |
| 17544542 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | December 2021 | July 2022 | Allow | 8 | 1 | 0 | No | No |
| 17525714 | METHODS AND COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES TO TREAT CANCER | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17522538 | GENETICALLY MODIFIED STEM CELLS | November 2021 | April 2023 | Allow | 17 | 2 | 0 | No | No |
| 17494633 | T CELL MANUFACTURING COMPOSITIONS AND METHODS | October 2021 | November 2024 | Allow | 37 | 1 | 1 | No | No |
| 17493411 | STEM CELL FACTOR INHIBITOR | October 2021 | December 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17490691 | ACTIVATION OF MARROW INFILTRATING LYMPHOCYTES IN HYPOXIC ALTERNATING WITH NORMOXIC CONDITIONS | September 2021 | November 2024 | Allow | 37 | 1 | 0 | No | No |
| 17480534 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | September 2021 | February 2022 | Allow | 5 | 1 | 0 | No | No |
| 17480587 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | September 2021 | February 2022 | Allow | 5 | 1 | 0 | No | No |
| 17480596 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | September 2021 | April 2022 | Allow | 7 | 1 | 0 | No | No |
| 17480525 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | September 2021 | February 2022 | Allow | 4 | 1 | 0 | No | No |
| 17478875 | METHODS OR GENERATING T-CELLS FROM STEM CELLS AND IMMUNOTHERAPEUTIC METHODS USING THE T-CELLS | September 2021 | December 2024 | Allow | 39 | 1 | 1 | No | No |
| 17465759 | MODIFIED B CELLS AND METHODS OF USE THEREOF | September 2021 | November 2023 | Allow | 26 | 3 | 1 | Yes | No |
| 17464115 | USE OF MONENSIN TO REGULATE GLYCOSYLATION OF RECOMBINANT PROTEINS | September 2021 | March 2022 | Allow | 6 | 1 | 0 | No | No |
| 17412617 | PLASMID COMBINATION AND APPLICATION THEREOF IN PREPARING MODIFIED IMMUNE CELLS | August 2021 | July 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17406212 | Growth and Survival Compositions for Cells Capable of Producing Antibodies and Methods Related Thereto | August 2021 | August 2024 | Allow | 36 | 1 | 0 | No | No |
| 17405918 | Methods of Culturing and Characterizing Antibody Secreting Cells | August 2021 | July 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17387357 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2021 | March 2022 | Allow | 8 | 1 | 0 | No | No |
| 17383276 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2021 | January 2022 | Allow | 6 | 1 | 0 | No | No |
| 17383272 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2021 | November 2021 | Allow | 3 | 1 | 0 | No | No |
| 17383280 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2021 | February 2022 | Allow | 6 | 1 | 0 | No | No |
| 17382831 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2021 | December 2021 | Allow | 5 | 1 | 0 | No | No |
| 17380388 | Exosomes For Delivery Of Biotherapeutics | July 2021 | November 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17376304 | METHOD FOR INHIBITING BONE RESORPTION | July 2021 | June 2025 | Allow | 47 | 2 | 0 | No | No |
| 17360886 | FUNCTIONAL VALIDATION OF DONOR IMMUNE-REGULATORY CELLS | June 2021 | November 2024 | Abandon | 41 | 1 | 2 | No | No |
| 17353430 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | June 2021 | December 2021 | Allow | 6 | 1 | 0 | No | No |
| 17351053 | IDENTIFYING HUMAN B CELLS EXPRESSING ANTI-ALLERGEN ANTIBODIES | June 2021 | January 2023 | Allow | 19 | 4 | 0 | Yes | No |
| 17330378 | Immune Cells with DNMT3A Gene Modifications and Methods Related Thereto | May 2021 | June 2024 | Allow | 36 | 1 | 0 | No | No |
| 17326088 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | May 2021 | October 2021 | Allow | 5 | 1 | 0 | No | No |
| 17289616 | METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-VEGF ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | April 2021 | April 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17226609 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | April 2021 | October 2021 | Allow | 7 | 1 | 0 | No | No |
| 17226624 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | April 2021 | October 2021 | Allow | 7 | 1 | 0 | No | No |
| 17226595 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | April 2021 | October 2021 | Allow | 7 | 1 | 0 | No | No |
| 17222833 | GENETICALLY MODIFIED STEM CELLS | April 2021 | September 2021 | Allow | 6 | 1 | 0 | No | No |
| 17198751 | COMBINED ORGAN AND HEMATOPOIETIC CELLS FOR TRANSPLANTATION TOLERANCE OF GRAFTS | March 2021 | July 2021 | Allow | 5 | 1 | 0 | No | No |
| 17185386 | NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION | February 2021 | April 2025 | Allow | 50 | 2 | 1 | No | Yes |
| 17184237 | CELL PENETRATING CONJUGATES AND METHODS OF USE THEREOF | February 2021 | June 2025 | Allow | 52 | 2 | 1 | No | No |
| 17182457 | Culture Medium for Expanding Breast Epithelial Stem Cells | February 2021 | August 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17148508 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | January 2021 | July 2021 | Allow | 6 | 1 | 0 | No | No |
| 17148475 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | January 2021 | May 2021 | Allow | 4 | 1 | 0 | No | No |
| 17147412 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | January 2021 | July 2024 | Allow | 43 | 2 | 0 | No | No |
| 17147080 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | January 2021 | August 2024 | Allow | 43 | 2 | 0 | No | No |
| 17146663 | COMPOSITIONS CONTAINING PLATELET CONTENTS | January 2021 | August 2024 | Allow | 43 | 1 | 1 | No | No |
| 17147073 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | January 2021 | April 2021 | Allow | 3 | 1 | 0 | No | No |
| 17147096 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | January 2021 | October 2024 | Allow | 46 | 2 | 1 | No | No |
| 17147090 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | January 2021 | May 2021 | Allow | 4 | 1 | 0 | No | No |
| 17137337 | COMPOSITIONS AND METHODS FOR NON-MYELOABLATIVE CONDITIONING | December 2020 | July 2024 | Allow | 43 | 1 | 1 | No | No |
| 17127768 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2020 | March 2021 | Allow | 3 | 1 | 0 | No | No |
| 17127795 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2020 | March 2021 | Allow | 3 | 1 | 0 | No | No |
| 17127790 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2020 | March 2021 | Allow | 3 | 1 | 0 | No | No |
| 17127840 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2020 | April 2021 | Allow | 4 | 1 | 0 | No | No |
| 17110207 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2020 | June 2021 | Allow | 6 | 1 | 0 | No | No |
| 17110179 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2020 | August 2024 | Allow | 44 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BELYAVSKYI, MICHAIL A.
With a 43.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BELYAVSKYI, MICHAIL A works in Art Unit 1644 and has examined 1,426 patent applications in our dataset. With an allowance rate of 56.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner BELYAVSKYI, MICHAIL A's allowance rate of 56.6% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BELYAVSKYI, MICHAIL A receive 1.82 office actions before reaching final disposition. This places the examiner in the 55% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BELYAVSKYI, MICHAIL A is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +36.1% benefit to allowance rate for applications examined by BELYAVSKYI, MICHAIL A. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.7% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 34.3% of cases where such amendments are filed. This entry rate is in the 43% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 28.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 28% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 71.9% of appeals filed. This is in the 55% percentile among all examiners. Of these withdrawals, 75.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 44.6% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 4.2% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.